Cas:132946-21-5 3-Morpholinecarboxylicacid,ethylester,(S)-(9CI) manufacturer & supplier

Chemical Name:3-Morpholinecarboxylicacid,ethylester,(S)-(9CI)

CAS.NO:132946-21-5

Synonyms:3-Morpholinecarboxylicacid,ethylester,(S)-(9CI)

Molecular Formula:C₇H₁₃NO₃

Molecular Weight:159.18300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:47.56000

Exact Mass:159.09000

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Morpholinecarboxylicacid,ethylester,(S)-(9CI) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Morpholinecarboxylicacid,ethylester,(S)-(9CI) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Morpholinecarboxylicacid,ethylester,(S)-(9CI) Use and application,3-Morpholinecarboxylicacid,ethylester,(S)-(9CI) technical grade,usp/ep/jp grade.

Related News: China has granted conditional approval to its first self-developed treatment for Alzheimer��s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug. 3-Morpholinecarboxylicacid,ethylester,(S)-(9CI) manufacturer Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. 3-Morpholinecarboxylicacid,ethylester,(S)-(9CI) supplier The primary endpoint of INSPIRE is overall survival. The trial continued beyond the pre-specified interim analysis and is nearing its conclusion. 3-Morpholinecarboxylicacid,ethylester,(S)-(9CI) vendor The primary endpoint of INSPIRE is overall survival. The trial continued beyond the pre-specified interim analysis and is nearing its conclusion. 3-Morpholinecarboxylicacid,ethylester,(S)-(9CI) factory Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical.